Date: 2015-02-03
Type of information: Nomination
Compound:
Company: Epizyme (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On February 3, 2015, Epizyme, a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced that Andrew Singer will join the Company as Chief Financial Officer on February 9th . Mr. Singer brings nearly 20 years of financial experience in the life sciences field and was previously Managing Director, Healthcare Investment Banking, in the Life Sciences Group at RBC Capital Markets Corporation , part of RBC Financial Group . Since joining RBC in 2004, Mr. Singer assisted clients with raising over $6 billion in equity, equity-linked and debt financings, and advised corporate clients on mergers and acquisitions. Prior to RBC, Mr. Singer worked at Petkevitch and Company , a life sciences investment bank, and co-founded MVC Capital, a business development company focused on debt and private equity investments. He is a member of the Board of Directors of the J. F. Kapnek Trust , the largest pediatric HIV/AIDS transmission prevention program in Zimbabwe , Africa . Mr. Singer received a B.A. from Yale University in 1992 and an M.B.A. from Harvard University Graduate School of Business in 1997.
Financial terms:
Latest news:
